Profile data is unavailable for this security.
About the company
Sumitomo Pharma Co Ltd, formerly Sumitomo Dainippon Pharma Co Ltd, is a Japan-based pharmaceutical company. The Company operates its business through four segments. The Japan segment is engaged in the manufacture, purchase, and sale of ethical drugs. The North American segment is engaged in the manufacture, purchase, and sale of ethical drugs and conducts research and development in the areas of oncology, urology, respiratory disease, and regenerative cell medicine. The China segment is engaged in the manufacture (small packaged products) and sale of ethical pharmaceuticals. The Overseas Others segment is engaged in the manufacture and sale of ethical pharmaceuticals in Europe. The segment also purchase and sell ethical pharmaceuticals in Southeast Asia and Taiwan, as well as provide information and collection activities for the Company's products. Other business includes manufacturing, purchasing, and sales of food ingredients, food additives and chemical product materials.
- Revenue in JPY (TTM)314.56bn
- Net income in JPY-314.97bn
- Incorporated1897
- Employees4.98k
- LocationSumitomo Pharma Co Ltd2-6-8, Dosho-machi, Chuo-kuOSAKA-SHI 541-0045JapanJPN
- Phone+81 662035321
- Fax+81 662026028
- Websitehttps://www.sumitomo-pharma.co.jp/
More ▼
Mergers & acquisitions
| Acquired company | 4506:TYO since announced | Transaction value |
|---|---|---|
| Nabriva Therapeutics PLC - Lefamulin Assets | -32.11% | 15.00m |
Data delayed at least 20 minutes, as of Jul 17 2024 02:19 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JCR Pharmaceuticals Co Ltd | 42.87bn | 5.51bn | 82.35bn | 934.00 | 14.46 | 1.41 | 9.43 | 1.92 | 43.92 | 43.92 | 342.31 | 450.13 | 0.4349 | 0.5891 | 3.29 | 45,900,430.00 | 5.62 | 8.66 | 8.47 | 13.46 | 72.90 | 74.51 | 12.92 | 18.24 | 1.22 | 27.69 | 0.2932 | 30.60 | 24.83 | 13.11 | 46.00 | 8.19 | 18.54 | 21.67 |
| Torii Pharmaceutical Co Ltd | 56.28bn | 5.29bn | 109.87bn | 583.00 | 20.29 | 0.9007 | 19.13 | 1.95 | 188.05 | 188.05 | 2,002.44 | 4,235.56 | 0.4288 | 2.72 | 2.25 | 96,531,740.00 | 4.03 | 6.52 | 4.44 | 7.35 | 44.83 | 49.55 | 9.40 | 17.98 | 5.58 | -- | 0.00 | 24.17 | 11.74 | -2.67 | 4.44 | 28.76 | -20.38 | 20.11 |
| Kyorin Pharmaceutical Co Ltd | 119.53bn | 5.32bn | 111.00bn | 2.04k | 18.64 | 0.7591 | 11.55 | 0.9286 | 92.70 | 92.70 | 2,082.82 | 2,276.51 | 0.6759 | 1.34 | 2.61 | 58,536,730.00 | 3.01 | 3.05 | 3.90 | 3.79 | 43.01 | 47.11 | 4.45 | 4.76 | 1.45 | -- | 0.1389 | 67.74 | 5.53 | 1.02 | 12.68 | -4.98 | 7.41 | -7.06 |
| Zeria Pharmaceutical Co Ltd | 75.73bn | 7.73bn | 114.21bn | 1.78k | 12.26 | 1.19 | 7.49 | 1.51 | 175.39 | 175.39 | 1,717.90 | 1,806.33 | 0.5304 | 1.48 | 3.99 | 42,614,000.00 | 5.39 | 3.89 | 8.39 | 6.28 | 73.29 | 71.93 | 10.16 | 7.57 | 0.7946 | 11.75 | 0.3735 | 35.09 | 10.74 | 4.14 | 24.78 | 17.49 | 20.77 | 5.29 |
| Mochida Pharmaceutical Co Ltd | 102.89bn | 4.55bn | 126.27bn | 1.52k | 26.68 | 0.9336 | 17.17 | 1.23 | 126.33 | 126.33 | 2,868.83 | 3,609.59 | 0.6478 | 1.86 | 3.28 | 67,598,550.00 | 2.86 | 4.37 | 3.44 | 5.31 | 50.61 | 52.47 | 4.42 | 6.71 | 3.31 | -- | 0.0029 | 45.16 | -0.3641 | -1.26 | -31.61 | -11.63 | 10.91 | -1.21 |
| Nxera Pharma Co Ltd | 16.43bn | -9.07bn | 151.04bn | 350.00 | -- | 2.28 | -- | 9.19 | -107.30 | -107.30 | 194.96 | 736.60 | 0.1309 | -- | 5.77 | 46,954,280.00 | -7.23 | -0.6588 | -7.78 | -0.7036 | 74.44 | 89.83 | -55.20 | -4.46 | 4.03 | -10.91 | 0.5238 | -- | -18.00 | -- | -1,982.98 | -- | -- | -- |
| Towa Pharmaceutical Co Ltd | 227.93bn | 16.17bn | 157.38bn | 4.59k | 9.30 | 0.9646 | 4.62 | 0.6905 | 328.58 | 328.58 | 4,630.88 | 3,167.26 | 0.5684 | 1.51 | 3.70 | 49,680,470.00 | 4.03 | 4.21 | 5.03 | 5.63 | 35.70 | 39.23 | 7.10 | 7.23 | 1.46 | -- | 0.5649 | 21.01 | 9.13 | 16.74 | 634.80 | 3.72 | 28.20 | 10.86 |
| Kissei Pharmaceutical Co Ltd | 75.58bn | 11.16bn | 160.51bn | 1.78k | 13.20 | 0.654 | 10.33 | 2.12 | 246.57 | 246.57 | 1,669.95 | 4,977.43 | 0.3135 | 1.56 | 2.94 | 42,483,980.00 | 4.68 | 3.61 | 5.05 | 3.90 | 49.41 | 49.47 | 14.94 | 12.69 | 4.43 | -- | 0.0078 | 34.87 | 11.98 | 0.8919 | 6.00 | 15.28 | 6.58 | 10.40 |
| Sumitomo Pharma Co Ltd | 314.56bn | -314.97bn | 163.93bn | 4.98k | -- | 1.05 | -- | 0.5212 | -792.79 | -792.79 | 791.76 | 392.82 | 0.308 | 1.21 | 4.05 | 63,164,260.00 | -30.84 | -5.07 | -54.58 | -7.73 | 59.76 | 69.99 | -100.12 | -12.28 | 0.2992 | -- | 0.7332 | -- | -43.38 | -7.29 | -322.71 | -- | 4.02 | -- |
| KAKEN PHARMACEUTICAL CO., LTD. | 72.04bn | 8.03bn | 186.42bn | 1.14k | 19.07 | 1.07 | 17.30 | 2.59 | 212.76 | 212.76 | 1,909.11 | 3,796.04 | 0.4264 | 2.05 | 3.40 | 63,474,890.00 | 4.75 | 6.83 | 5.40 | 7.87 | 53.49 | 54.78 | 11.14 | 14.48 | 4.72 | -- | 0.0261 | 51.25 | -1.29 | -5.21 | 47.52 | -14.70 | 0.3639 | 0.00 |
Data as of Jul 17 2024. Currency figures normalised to Sumitomo Pharma Co Ltd's reporting currency: Japanese Yen JPY
11.64%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nomura Asset Management Co., Ltd.as of 31 May 2024 | 13.53m | 3.40% |
| Nikko Asset Management Co., Ltd.as of 05 Jul 2024 | 6.86m | 1.72% |
| Daiwa Asset Management Co. Ltd.as of 28 Jun 2024 | 6.40m | 1.61% |
| The Vanguard Group, Inc.as of 04 Jul 2024 | 6.01m | 1.51% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 05 Jul 2024 | 3.41m | 0.86% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 2.88m | 0.73% |
| Dimensional Fund Advisors LPas of 04 Jul 2024 | 2.39m | 0.60% |
| BlackRock Fund Advisorsas of 03 Jul 2024 | 1.95m | 0.49% |
| BlackRock Japan Co. Ltd.as of 04 Jul 2024 | 1.47m | 0.37% |
| Charles Schwab Investment Management, Inc.as of 03 Jul 2024 | 1.42m | 0.36% |
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
